Stem Point Capital LP Neurocrine Biosciences Inc Transaction History
Stem Point Capital LP
- $314 Billion
- Q1 2025
A detailed history of Stem Point Capital LP transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Stem Point Capital LP holds 21,052 shares of NBIX stock, worth $2.63 Million. This represents 0.74% of its overall portfolio holdings.
Number of Shares
21,052Holding current value
$2.63 Million% of portfolio
0.74%Shares
2 transactions
Others Institutions Holding NBIX
# of Institutions
648Shares Held
96.9MCall Options Held
800KPut Options Held
565K-
Black Rock Inc. New York, NY14.2MShares$1.77 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.94MShares$1.24 Billion0.02% of portfolio
-
Dodge & Cox San Francisco, CA5.53MShares$692 Million0.37% of portfolio
-
State Street Corp Boston, MA4.86MShares$608 Million0.02% of portfolio
-
Jpmorgan Chase & CO New York, NY2.67MShares$334 Million0.02% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $12B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...